
Photo from Vadim Koshkin/X
Jun 1, 2024, 23:26
Vadim Koshkin: Our recent work highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab
Vadim Koshkin, Assistant Professor at University of California, San Francisco, shared a post on X/Twitter:
”Our recent work in European Urology Focus with Jason Brown, Case Comp Cancer Center highlighting a Grey Zone in metastatic urothelial carcinoma after enfortumab vedotin/pembrolizumab.
Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape.”
Source: Vadim Koshkin/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 30, 2025, 23:21
Mar 30, 2025, 18:52
Mar 30, 2025, 18:31